Orthocell has shared that it has completed the first commercial sales of Remplir™ in Canada, marking a key milestone in the Company’s global commercialisation strategy for its flagship nerve repair medical device.
Remplir™ RWE study delivers 90% success rate
Orthocell has announced compelling new data from its ongoing Remplir™ Real World Evidence (RWE) study, demonstrating strong and consistent clinical outcomes across a broad range of peripheral nerve repair procedures.
Orthocell reports continued growth and strong US momentum in March 2026 quarter
Orthocell (ASX:OCC) has released its Quarterly Report for the quarter ended 31 March 2026, highlighting continued revenue growth, strong commercial traction in the United States, and expanding global adoption of Remplir™.
First Remplir™ Surgical Case Completed in U.S. Department of Defense Hospital Network
Orthocell has shared that the first surgical case using Remplir™ has been successfully completed within the U.S. Department of Defense (DoD) / Veterans Affairs (VA) hospital network, shortly after the Company announced approval to supply Remplir into these hospital systems.
Orthocell secures Remplir™ approval across U.S. Department of Defence Hospital Network
Orthocell has secured approval for Remplir™ to be used across the United States Department of Defence and Veterans Affairs (VA) hospital networks, marking a significant step forward in the Company’s U.S. commercial strategy.
Remplir™ Exempt from US Pharma Tariffs Due to Medical Device Status
Recent coverage has highlighted that Orthocell’s flagship nerve repair product, Remplir™, is expected to be exempt from newly proposed US tariffs targeting pharmaceutical imports.
Investor Presentations | March 2026
Orthocell CEO and MD, Paul Anderson, presented at two investor-facing events on 31 March 2026, providing an in-depth update on the Company’s commercial progress and global expansion strategy.
The Armchair Analyst | What makes a surgeon adopt a product?
Surgeon adoption is a key factor in the commercialisation of medical technologies. But what influences whether a surgeon chooses to adopt a new product in clinical practice?
Remplir™ Used in 23 Surgeries on Injured Soldiers in Ukraine
Orthocell has announced that its Remplir™ nerve repair device has been used in 23 surgical procedures on injured soldiers in Ukraine.
February 2026 Orthocell Investor Webinar Replay
In this webinar, Orthocell Chair, John Van Der Wielen, CEO and MD, Paul Anderson, and Independent Director, Dr Ravi Thadani provide an important operational update on the US roll out of Remplir™.